Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly

NCT04076462 is registered in ClinicalTrials.gov with Camurus AB as lead sponsor.

NCT NCT04076462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04076462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly
Lead sponsor
Camurus AB
Phase
Phase 3
Overall status
Completed
Start date
August 19, 2019
Completion date
May 2, 2023
Enrollment
72 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly